Chemotherapy Combined with Immunotherapy and Targeted Therapy in Advanced Intrahepatic Cholangiocarcinoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically or radiologically confirmed intrahepatic cholangiocarcinoma
• Initially treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI inhibitors
Locations
Other Locations
China
2nd Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING
Hangzhou
Contact Information
Primary
Weilin Wang, PHD
wam@zju.edu.cn
+86 057187783820
Backup
Yuan Ding, PHD
dingyuan@zju.edu
+86 18858101960
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2025-05-31
Participants
Target number of participants: 300
Treatments
Control group
Patients initially received GP/GEMOX regimen.
Experimental group
Patients initially received GP/GEMOX combined with PD-1/L1 and TKI inhibitors regimen.
Related Therapeutic Areas
Sponsors
Leads: Second Affiliated Hospital, School of Medicine, Zhejiang University